Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. - sprookjes - yvandenbroek - TriplyDB

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

http://www.wikidata.org/entity/Q46658463

about

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin Trabectedin for advanced soft tissue sarcomas: optimizing use Alkaloids from marine invertebrates as important leads for anticancer drugs discovery and development Trabectedin in soft tissue sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Role of trabectedin in the treatment of soft tissue sarcoma Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcoma Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors Current status on marine products with reversal effect on cancer multidrug resistance.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom Emerging drugs for the treatment of soft tissue sarcomas.Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Role of chemotherapy in the management of soft tissue sarcomas.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Histology-driven chemotherapy in soft tissue sarcomas.

P2860

Q26738346-729BFAFC-8C18-4E32-AD2F-68CE37AC6237 Q26860365-B1495B5A-896D-46FF-B581-F035BC384432 Q27012072-25B079AF-BDFA-444B-8270-FE4D34A6B859 Q28085505-6192E055-50A4-4E9B-9C26-AFB7873D227E Q28087771-A71F1CDC-69EA-4F79-AE56-E967DA14B58F Q30439459-3B5AC7FE-00C5-4877-8246-5A15BE817F98 Q33359943-5B9D748A-0CE6-48AC-B69D-F19DE8258D2F Q33379886-0F426D7B-8D4E-423E-AED8-CE45F8352E56 Q33380903-76E00249-5A7E-46FD-A10D-3CB85CE56F6B Q33381641-875BF7C2-F6B5-4F0A-8144-F29A04C97786 Q33384836-3FE9FD5A-E05A-4D6D-A465-4233FC568860 Q33386535-5175CF40-1B11-4967-ABA2-D07211F379A0 Q33392364-51F04F2A-4E33-49FD-A8EB-EBF0FC27D68E Q33426789-66330553-C150-491B-B408-D171DB2CB9FC Q33850011-F0252149-78BF-4244-92EA-37FF0DAFB7CB Q33916011-0659070E-FB21-4E29-9BD0-65C1845D0FC9 Q34166391-8CA45CE7-4F34-4356-9E71-5B67A1BEE533 Q34356540-B777D658-8650-49BD-A9E5-3F4DE1108087 Q34578850-92CDC2AB-9637-4DD9-AB7F-8097A37B5FBA Q34622323-5F8158E1-72B3-440B-8603-21E193C5225A Q34628607-886D1E88-F204-48D6-8C2C-26C6D3D8DAC7 Q34647970-6D8D0AB6-7A7F-4BC6-A355-93D48AD9045C Q35215703-1433D49B-6182-4EDD-8C26-4CB4180390C4 Q35898258-91ADB1CA-4D2D-464B-B7A9-EEA8AC316CA3 Q35909766-69392B61-9960-4472-A16F-C29F8B2DB253 Q36233516-0718D650-1F24-4B90-BA1C-966780CDD09E Q36395803-4EE3F6E6-D235-41F4-A2C7-0E2B81F19DC6 Q36444369-65268760-DD40-4FDB-BB67-8A30D7017C41 Q36514001-101E35B4-AC3E-4047-A09C-6C04E10165F5 Q36530034-CAE7DB40-0FDF-4E86-B093-3B6D5D8A5ECF Q36567662-1A6CC5D9-8589-45D1-821E-A18913E60DAC Q36616537-41915332-1681-47E7-A6F2-C908DD74C9B8 Q36731032-2F29E900-E5EB-4BA1-A435-71C8F8197D6C Q36758596-A9F546B7-4D98-4C8D-9A09-8879F3D7025C Q36895793-16913B3E-5C5F-4BFF-A0DA-F9DA23509BF5 Q37214309-1945E8AB-0E3B-4619-971E-38D7568EB8CA Q37330372-F711FC6E-A752-436D-B625-EFCFB5213A5C Q37687389-7D1B3BAD-9DA9-4C87-8FD4-03A575A1FEFC Q37760957-57C922B8-5D1E-4E59-95AE-C22A5C0F46B8 Q37848174-9D4CDC1C-C763-4534-8249-4A06826082E6

P2860

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

http://www.wikidata.org/entity/Q46658463

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Ecteinascidin-743 (ET-743) for ...... II and pharmacokinetic study.

@en

Ecteinascidin-743

@nl

type

label

Ecteinascidin-743 (ET-743) for ...... II and pharmacokinetic study.

@en

Ecteinascidin-743

@nl

prefLabel

Ecteinascidin-743 (ET-743) for ...... II and pharmacokinetic study.

@en

Ecteinascidin-743

@nl

P1433

Q46658463-0C622C69-518D-4347-A149-5C41F1EA9231

P1476

Q46658463-2E159002-78E4-4C58-B49D-1D79362C79EB

P2093

Q46658463-05710F71-6DD4-4748-9555-43582916AF7C

Q46658463-0CB61F45-310B-4E25-A5A5-F02037BAD5DE

Q46658463-136D80D4-F05D-4DCC-8D56-C8488A7BCF7D

Q46658463-181A3067-96C3-4A67-A242-1B8E6906F974

Q46658463-378AB9CE-F9F1-4349-B0A6-05C88D622188

Q46658463-42624A30-D669-41EB-87B3-160692457FC5

Q46658463-713FD6E0-8BB0-4752-B601-93F4AA2A55A3

Q46658463-71AF0778-929E-4E6A-8D66-73A8223124E8

Q46658463-89E98CFA-CD08-4D24-9131-A0B9092E0F6F

Q46658463-AA9AA8BF-ACB8-45E6-BD65-7A07F1326D51

P304

Q46658463-46770501-FCEF-4D83-950D-1E9D16EE934F

P31

Q46658463-AB55B592-2FC6-4F17-9456-0F01F4815016

P356

Q46658463-E0D238F7-8945-4DC3-A964-E7E27D5126EE

P407

Q46658463-6CE6DB8F-A303-4080-ABE4-7ED5E5CC6BD0

P433

Q46658463-AC3A47DB-06A9-4A11-AB17-FB0F471B3EA8

P478

Q46658463-4CE5DE9F-6F82-43A3-98F5-564F742BD518

P577

Q46658463-F11A2160-E7E3-4BD5-8A13-D7F385ADA6C4

P698

Q46658463-A60CAA60-E1F7-4D6C-9441-57F6F223A798

P921

Q46658463-B1865AA4-936C-49E1-A3A9-8B7EEF0FDBD2

P356

JCO.2005.05.028

P1433

Journal of Clinical Oncology

P1476

Ecteinascidin-743 (ET-743) for ...... II and pharmacokinetic study.

@en

P2093

A Waxman

http://www.w3.org/2001/XMLSchema#string

C Guzman

http://www.w3.org/2001/XMLSchema#string

D Harmon

http://www.w3.org/2001/XMLSchema#string

D P Ryan

http://www.w3.org/2001/XMLSchema#string

G D Demetri

http://www.w3.org/2001/XMLSchema#string

G Goss

http://www.w3.org/2001/XMLSchema#string

J G Supko

http://www.w3.org/2001/XMLSchema#string

J Jimeno

http://www.w3.org/2001/XMLSchema#string

J Manola

http://www.w3.org/2001/XMLSchema#string

M A Sancho

http://www.w3.org/2001/XMLSchema#string

P304

5484-5492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.028

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16110008

http://www.w3.org/2001/XMLSchema#string

P921